NOX66 as Monotherapy, and in Combination With Carboplatin, in Patients With Refractory Solid Tumors: Phase Ia/b Study

• Үндсэн зохиолчид: Koba Kiknavelidze, PhD (Зохиогч), Mikheil Shavdia, PhD (Зохиогч), Nana Chikhladze, PhD (Зохиогч), Lia Abshilava, PhD (Зохиогч), Marinella Messina, PhD (Зохиогч), Gisela Mautner, MD, PhD (Зохиогч), Graham Kelly, PhD (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Elsevier, 2021-01-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

ABSTRACT: Background: Although oral and intravenous forms of idronoxil have been well tolerated, the safety of NOX66, with idronoxil formulated as a rectal suppository, is not known. This Phase Ia/b clinical study (protocol No. NOX66-001A), known as Chemotherapy Enhancement Program-1, is the first t...